Summary: Changes in bone mineral density and bone strength following treatment with zoledronic acid (ZOL) were measured by quantitative computed analysis (QCT) or dual-energy X-ray absorptiometry (DXA). ZOL treatment increased spine and hip BMD vs placebo, assessed by QCT and DXA. Changes in trabecular bone resulted in increased bone strength. Introduction: To investigate bone mineral density (BMD) changes in trabecular and cortical bone, estimated by quantitative computed analysis (QCT) or dual-energy X-ray absorptiometry (DXA), and whether zoledronic acid 5 mg (ZOL) affects bone strength. Methods: In 233 women from a randomized, controlled trial of once-yearly ZOL, lumbar spine, total hip, femoral neck, and trochanter were assessed by DXA and QCT (baseline, Month 36). Mean percentage changes from baseline and between-treatment differences (ZOL vs placebo, t-test) were evaluated. Results: Mean between-treatment differences for lumbar spine BMD were significant by DXA (7.0%, p<0.01) and QCT (5.7%, p<0.0001). Between-treatment differences were significant for trabecular spine (p=0.0017) [non-parametric test], trabecular trochanter (10.7%, p<0.0001), total hip (10.8%, p<0.0001), and compressive strength indices at femoral neck (8.6%, p=0.0001), and trochanter (14.1%, p<0.0001). Conclusions: Once-yearly ZOL increased hip and spine BMD vs placebo, assessed by QCT vs DXA. Changes in trabecular bone resulted in increased indices of compressive strength. © International Osteoporosis Foundation and National Osteoporosis Foundation 2009.

Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: Results of the HORIZON pivotal fracture trial / R., Eastell; T., Lang; S., Boonen; S., Cummings; P. D., Delmas; J. A., Cauley; Z., Horowitz; E., Kerzberg; G., Bianchi; D., Kendler; P., Leung; Z., Man; P., Mesenbrink; E. F., Eriksen; D. M., Black; Minisola, Salvatore; Horizon Pivotal Fracture, Trial. - In: OSTEOPOROSIS INTERNATIONAL. - ISSN 0937-941X. - 21:7(2010), pp. 1277-1285. [10.1007/s00198-009-1077-9]

Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: Results of the HORIZON pivotal fracture trial

MINISOLA, Salvatore;
2010

Abstract

Summary: Changes in bone mineral density and bone strength following treatment with zoledronic acid (ZOL) were measured by quantitative computed analysis (QCT) or dual-energy X-ray absorptiometry (DXA). ZOL treatment increased spine and hip BMD vs placebo, assessed by QCT and DXA. Changes in trabecular bone resulted in increased bone strength. Introduction: To investigate bone mineral density (BMD) changes in trabecular and cortical bone, estimated by quantitative computed analysis (QCT) or dual-energy X-ray absorptiometry (DXA), and whether zoledronic acid 5 mg (ZOL) affects bone strength. Methods: In 233 women from a randomized, controlled trial of once-yearly ZOL, lumbar spine, total hip, femoral neck, and trochanter were assessed by DXA and QCT (baseline, Month 36). Mean percentage changes from baseline and between-treatment differences (ZOL vs placebo, t-test) were evaluated. Results: Mean between-treatment differences for lumbar spine BMD were significant by DXA (7.0%, p<0.01) and QCT (5.7%, p<0.0001). Between-treatment differences were significant for trabecular spine (p=0.0017) [non-parametric test], trabecular trochanter (10.7%, p<0.0001), total hip (10.8%, p<0.0001), and compressive strength indices at femoral neck (8.6%, p=0.0001), and trochanter (14.1%, p<0.0001). Conclusions: Once-yearly ZOL increased hip and spine BMD vs placebo, assessed by QCT vs DXA. Changes in trabecular bone resulted in increased indices of compressive strength. © International Osteoporosis Foundation and National Osteoporosis Foundation 2009.
2010
bisphosphonates; bone densitometry; bone qct; clinical trials; osteoporosis
01 Pubblicazione su rivista::01a Articolo in rivista
Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: Results of the HORIZON pivotal fracture trial / R., Eastell; T., Lang; S., Boonen; S., Cummings; P. D., Delmas; J. A., Cauley; Z., Horowitz; E., Kerzberg; G., Bianchi; D., Kendler; P., Leung; Z., Man; P., Mesenbrink; E. F., Eriksen; D. M., Black; Minisola, Salvatore; Horizon Pivotal Fracture, Trial. - In: OSTEOPOROSIS INTERNATIONAL. - ISSN 0937-941X. - 21:7(2010), pp. 1277-1285. [10.1007/s00198-009-1077-9]
File allegati a questo prodotto
File Dimensione Formato  
Eastell_Effect of once-yearly zoledronic acid_2016.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 192.08 kB
Formato Adobe PDF
192.08 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/106772
Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 39
  • ???jsp.display-item.citation.isi??? 30
social impact